

Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Packet Meeting – August 9, 2023

NOTE: *No live August meeting. August 2023 is a packet-only meeting.*

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. DUR Board Meeting Minutes – See Appendix A

- A. July 12, 2023 DUR Board Meeting Minutes
- B. July 12, 2023 DUR Board Recommendations Memorandum

Items to be presented by Dr. Wilson, Dr. Moss, Dr. Muchmore, Chairman:

2. Update on Medication Coverage Authorization Unit/U.S. Food and Drug Administration (FDA) Safety Alerts – See Appendix B

- A. Pharmacy Help Desk Activity for July 2023
- B. Medication Coverage Activity for July 2023
- C. FDA Safety Alerts

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

3. Annual Review of Various Systemic Antibiotics and 30-Day Notice to Prior Authorize Xacduro® (Sulbactam/Durlobactam) – See Appendix C

- A. Current Prior Authorization Criteria
- B. Utilization of Various Systemic Antibiotics
- C. Prior Authorization of Various Systemic Antibiotics
- D. Market News and Updates
- E. Xacduro® (Sulbactam/Durlobactam) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Various Systemic Antibiotics

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

4. Annual Review of Intravenous (IV) Iron Products – See Appendix D

- A. Current Prior Authorization Criteria
- B. Utilization of IV Iron Products
- C. Prior Authorization of IV Iron Products
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of IV Iron Products

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

5. Annual Review of Topical Corticosteroids – See Appendix E

- A. Current Prior Authorization Criteria
- B. Utilization of Topical Corticosteroids
- C. Prior Authorization of Topical Corticosteroids
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Topical Corticosteroids

Items to be presented by Dr. Reynolds, Dr. Muchmore, Chairman:

6. Annual Review of Opioid Analgesics and Medication-Assisted Treatment (MAT) Medications and 30-Day Notice to Prior Authorize Brixadi™ (Buprenorphine Extended-Release Injection), Nalocet® (Oxycodone/Acetaminophen Tablet), and Prolate™ (Oxycodone/Acetaminophen Tablet) – See Appendix F

- A. Current Prior Authorization Criteria
- B. Utilization of Opioid Analgesics and MAT Medications
- C. Prior Authorization of Opioid Analgesics and MAT Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Opioid Analgesics and MAT Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

7. 30-Day Notice to Prior Authorize Cuvrior™ (Trientine Tetrahydrochloride) – See Appendix G

- A. Introduction
- B. Cuvrior™ (Trientine Tetrahydrochloride) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

8. Annual Review of Camzyos® (Mavacamten) – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of Camzyos® (Mavacamten)
- C. Prior Authorization of Camzyos® (Mavacamten)
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Camzyos® (Mavacamten)

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

9. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix I

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

10. Future Business* (Upcoming Product and Class Reviews)

- A. Breast Cancer Medications
- B. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
- C. Synagis® (Palivizumab)
- D. Zinplava™ (Bezlotoxumab)

*Future product and class reviews subject to change.

11. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.